Answers are grounded in this paper and cite their sources.
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5-37) and GBP 1234 (569-2594) per patient.
No takes yet. Share an insight, caveat, or question.
Marks et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: